The Testaments takes place more than 15 years after the events of The Handmaid’s Tale and will pick back up inside the ...
Under U.S. law, most patents are limited to a term of 20 years from the earliest nonprovisional filing date. However, Patent Term Adjustment (PTA) ...
Hulu is nearing a series order for 'The Handmaid’s Tale' spinoff 'The Testaments' before the hit show's final season ...
The Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, ...
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive ...
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare ...
Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...
The Testaments, the sequel series to The Handmaid’s Tale, has cast a major leading role. The upcoming series, based on ...
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results